Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 559,931 | 331,147 | 279,048 | 230,042 | 265,876 |
| Receivables | 2,742 | 143 | N/A | 18,000 | N/A |
| TOTAL | $588,893 | $347,293 | $285,767 | $251,440 | $267,726 |
| Non-Current Assets | |||||
| PPE Net | 4,237 | 4,134 | 2,021 | 1,335 | 724 |
| Other Non-Current Assets | 22,756 | 18,598 | 18,993 | 2,476 | 993 |
| TOTAL | $26,993 | $22,732 | $21,014 | $3,811 | $1,717 |
| Total Assets | $615,886 | $370,025 | $306,781 | $255,251 | $269,443 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,602 | 5,450 | 3,339 | 3,645 | 2,149 |
| Accrued Expenses | 20,870 | 17,918 | 12,753 | 7,339 | 4,612 |
| TOTAL | $27,450 | $24,373 | $16,547 | $11,846 | $7,184 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 16,883 | 13,439 | 12,811 | 231 | 538 |
| TOTAL | $16,883 | $13,439 | $12,811 | $231 | $538 |
| Total Liabilities | $44,333 | $37,812 | $29,358 | $12,077 | $7,722 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 40,562 | 35,983 | 28,536 | 24,000 | 23,271 |
| Common Shares | 4 | 3 | 2 | 2 | 2 |
| Retained earnings | -568,779 | -381,426 | -228,434 | -123,755 | -65,011 |
| TOTAL | $571,553 | $332,213 | $277,423 | $243,174 | $261,721 |
| Total Liabilities And Equity | $615,886 | $370,025 | $306,781 | $255,251 | $269,443 |